Cantuzumab ravtansine

N/A

Report date: 2024/02/05 14:03:34

Base Information

Drug NameCantuzumab ravtansine

Drug Alias NameMonoclonal antibody C-242 DM4 conjugateC242 maytansinoid-4 conjugateC242 DM4 immunoconjugatehuC242-DM4IMGN-242 +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionApoptosis stimulantsMitosis inhibitorsMucin-1 inhibitors

TargetsTumor-associated carbohydrate antigen CanAgMucin-1

Therapy Area/IndicationsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunogen Inc

Active IndicationsN/A

Inactive IndicationsStomach Neoplasms

Other Information

ATC CodeN/A